Become a Member and get exclusive discounted Prices and Deals.
Test results include microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions, and loss of heterozygosity (LOH) for ovarian cancer patients. You can also order PD-L1 immunohistochemistry (IHC) testing* as an optional add-on test. We offer the option to reflex from FoundationOne CDx testing to FoundationOne®Liquid CDx if the tissue submitted does not meet the criteria for successful testing.
FoundationOne CDx has national coverage for qualifying Medicare and Medicare Advantage patients across all solid tumors.†